3-Bromopyruvate as a potent covalently reversible inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1)
Authors:
- 1 January 2020
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 142, 105161
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (21572179, 2019KW-068)
This publication has 36 references indexed in Scilit:
- Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative BacteriaAnnual Review of Microbiology, 2011
- Updated Functional Classification of β-LactamasesAntimicrobial Agents and Chemotherapy, 2010
- Three Decades of β-Lactamase InhibitorsClinical Microbiology Reviews, 2010
- Structure and Mechanism of Copper- and Nickel-Substituted Analogues of Metallo-β-lactamase L1Biochemistry, 2009
- Role of the Zn1and Zn2sites in Metallo-β-lactamase L1Journal of the American Chemical Society, 2008
- Minor extended-spectrum β-lactamasesClinical Microbiology and Infection, 2008
- New strategies for combating multidrug-resistant bacteriaTrends in Molecular Medicine, 2007
- Metallo-β-lactamases: Novel Weaponry for Antibiotic Resistance in BacteriaAccounts of Chemical Research, 2006
- Cytosolic and Nuclear Protein Targets of Thiol-Reactive ElectrophilesChemical Research in Toxicology, 2005
- Extended-Spectrum β-Lactamases: a Clinical UpdateClinical Microbiology Reviews, 2005